1. Home
  2. STDN vs GHRS Comparison

STDN vs GHRS Comparison

Compare STDN & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standard Nuclear Inc. Class A Common Stock

STDN

Standard Nuclear Inc. Class A Common Stock

N/A

Current Price

$13.08

Market Cap

1.9B

ML Signal

N/A

Logo GH Research PLC

GHRS

GH Research PLC

HOLD

Current Price

$27.96

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STDN
GHRS
Founded
N/A
2018
Country
Ireland
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
2026
2021

Fundamental Metrics

Financial Performance
Metric
STDN
GHRS
Price
$13.08
$27.96
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$41.38
AVG Volume (30 Days)
823.4K
131.9K
Earning Date
N/A
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.05
$12.04
52 Week High
$17.34
$31.44

Technical Indicators

Market Signals
Indicator
STDN
GHRS
Relative Strength Index (RSI) 51.34 49.14
Support Level $11.58 $26.39
Resistance Level $13.80 $28.96
Average True Range (ATR) 1.07 1.08
MACD -0.19 0.03
Stochastic Oscillator 28.48 54.71

Price Performance

Historical Comparison
STDN
GHRS

About STDN Standard Nuclear Inc. Class A Common Stock

Standard Nuclear Inc is an independent advanced nuclear fuel company. The company designs, engineers, and manufactures advanced nuclear fuels, with a primary focus on TRISO fuel for advanced reactors. Its operations include industrial-scale TRISO fuel manufacturing and the development of fuel for advanced reactors that utilize TRISO fuel. The company operates in a single operating and reportable segment, as it is engaged in a single business activity of TRISO production. It derives revenue from fuel development and services agreements. Geographically, the maximum revenue is generated from the United States.

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Share on Social Networks: